Open links in new tab
  1. Nature
    https://www.nature.com/articles/s41598-021-85930-y

    Advanced bioinformatic analysis and pathway prediction of

    • This study aims to identify pathway involvement in the development of cisplatin (cis-diamminedichloroplatinum (II); CDDP) resistance in A549 lung cancer (LC) cells by utilizing advanced bioinformatics softwar… See more

    Introduction

    Lung cancer (LC) represents ~ 13% of all new cancer cases and is the leading cause of … See more

    Nature
    Results

    A549 LC cells developed resistance after continuous and prolonged exposure to CDDP
    We evaluated A549/DDP cells' resistance developme… See more

    Nature
    Discussion

    Chemoresistance is a major challenge in cancer treatment and the cause of failure for various chemotherapeutic approaches20,21. The development of chemoresis… See more

    Nature
    Materials and methods

    Materials
    A549 human lung adenocarcinoma cell line was purchased from ATCC (Old Town Manassas, VA). Cisplatin was purchased from Acros … See more

    Nature
    Conclusions

    Chemoresistance is a significant hurdle in cancer treatment. Multiple pathways and cellular activities contribute to the manifestation of the phenotype. Here, we developed t… See more

    Nature
    What are the IC50 values of a549/ddp cells transfected with FANCL-siRNA?
    For instance, the IC50 values of A549/ DDP cells transfected with FANCL-siRNA were reduced from 34.15 μg/ml pre-transfection to 2.51 μg/ml post- transfection, whereas the IC50 values of A549 cells pre- and post-transfection were 4.97 μg/ml and 2.46 μg/ml, re- spectively ( Table 1 ).
    researchgate.net
    Feedback
    Table of Contents
    Introduction
    Results
    Discussion
    Materials and methods
    Conclusions
    What are the IC50 values of a549/ddp cells transfected with FANCL-siRNA?
     
  1. Studies of A549 IC50
    PubMed
    Cisplatin-resistant A549 non-small cell lung cancer cells can be identified by increased mitochondrial mass and are sensitive to pemetrexed treatment
    Background: Cisplatin plus pemetrexed combination therapy is considered the standard treatment for patients with advanced, non-squamous, non-small-cell lung cancer (NSCLC). However, advanced NSCLC has a 5-year survival rate of below 10%, which is mainly due to therapy resistance. We previously showe...
    Author: Yanyun Gao
    Published: 2019/11/29
    Keywords: Cisplatin pl…
    PubMed
    C-Myc participates in β-catenin-mediated drug resistance in A549/DDP lung adenocarcinoma cells
    The aim of this study was to investigate c-Myc and β-catenin-mediated drug resistance in A549/DDP lung adenocarcinoma cells. Cisplatin sensitivity was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) toxicity assay. β-Catenin and c-Myc protein expression following...
    Author: Chengyao Xie
    Published: 2014/12
    Keywords: C-Myc; dru…
    PubMed
    Overcoming acquired resistance of gefitinib in lung cancer cells without T790M by AZD9291 or Twist1 knockdown in vitro and in vivo
    The T790M mutation is recognized as a typical mechanism of acquired resistance to first generation of epithermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) such as gefitinib in non-small cell lung cancer (NSCLC) patients who are commonly treated by third generation of EGFR-TKI AZD...
    Author: Zhongwei Liu
    Published: 2019/6
    Keywords: AZD9291; …
    PubMed
    Therapeutic Delivery of MicroRNA-29b by Cationic Lipoplexes for Lung Cancer
    MicroRNA-29b (miR-29b) expression has been shown to be reduced in non-small-cell lung cancer (NSCLC) tissues. Here, we have identified the oncogene cyclin-dependent protein kinase 6 (CDK6) as a direct target of miR-29b in lung cancer. We hypothesized that in vivo restoration of miR-29b and thus targ...
    Author: Yun Wu
    Published: 2013/04/16
    Keywords: National In…
    National Center for Biotechnology Information
    ERK inactivation enhances stemness of NSCLC cells via promoting Slug-mediated epithelial-to-mesenchymal transition
    Rationale: The mitogen-activated protein kinase pathway (MAPK) is one of the major cancer-driving pathways found in non-small cell lung cancer (NSCLC) patients. ERK inhibitors (ERKi) have been shown to be effective in NSCLC patients with MAPK pathway mutations. However, like other MAPK inhibitors, E...
    Author: Shurui Cai, N…
    Published: 2022
    Publication: Theranost…
  2. Wiley Online Library
    https://onlinelibrary.wiley.com/doi/full/10.11…

    PD‐0332991 combined with cisplatin inhibits nonsmall …

    Feb 3, 2021 · Method: We used CCK-8 assay to got the IC50 of PD-0332991 and cisplatin in A549 and A549/CDDP respectively. CCK-8 assay, CalcuSyn 2.0 software, cell cycle distribution and apoptosis used to identify PD-0332991 …

  3. ResearchGate
    https://www.researchgate.net/figure/The-50...

    The 50 % inhibitory concentration (IC50) of cisplatin in …

    The 50 % inhibitory concentration (IC50) of cisplatin in A549 and A549/DDP cells 48 h after drug treatment. Source publication. +4. RNA interferences targeting the Fanconi anemia/BRCA pathway...

  4. ResearchGate
    https://www.researchgate.net/figure/IC-50-v…

    IC 50 values for cisplatin, curcuminoid, and …

    In this study, we investigated whether the curcuminoids, CLEFMA and EF24, improved cisplatin efficacy and reduced cisplatin ototoxicity. We used the lung cancer cell line, A549, to determine the...

  5. Frontiers
    https://www.frontiersin.org/journals/oncology...

    Deferoxamine Counteracts Cisplatin Resistance in A549 Lung ...

  6. PubMed
    https://pubmed.ncbi.nlm.nih.gov/31798346

    Cisplatin-resistant A549 non-small cell lung cancer cells can be ...

  7. PubMed
    https://pubmed.ncbi.nlm.nih.gov/25131138

    C-Myc participates in β-catenin-mediated drug resistance in …

  8. Nature
    https://www.nature.com/articles/s41419-01…

    Arsenic circumvents the gefitinib resistance by binding …

    Sep 20, 2018 · The IC50 values of arsenic in NCI-H1975 were 2 µM and >8 µM in HCC827 and A549. The IC50 values of gefitinib were 0.01 µM in HCC827 and 10 µM in NCI-H1975 and A549.

  9. Nature
    https://www.nature.com/articles/srep12291

    Hypoxia-induced autophagy mediates cisplatin resistance in lung …

  10. Open-i
    https://openi.nlm.nih.gov/detailedresult?img=PMC...

    Cells exhibit increased fold changes in IC50 concentrat | Open-i

  11. Some results have been removed